Study of Temzolomide and Gleevec in Advanced Melanoma

Phase 1/2 Terminated 32 enrolled Abramson Cancer Center at Penn Medicine Novartis Pharmaceuticals · collab

NaSingle-groupOpen-labelTreatment

Summary

This study has been designed to evaluate the side effects of Gleevec when given in combination with Temzolomide; and to learn more about how these drugs work in the body and whether this combination is useful in treating patients with melanoma.

Timeline

Start: 2003-01
Primary completion: 2011-03-09
Completion: 2011-03-09

Publications

Results Bajor DL, Xu X, Torigian DA, Mick R, Garcia LR, Richman LP, Desmarais C, Nathanson KL, Schuchter LM, Kalos M, Vonderheide RH. Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma. Cancer Immunol Res. 2014 Nov;2(11):1051-8. doi: 10.1158/2326-6066.CIR-14-0154. Epub 2014 Sep 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Imatinib	Small molecule	600 mg	—
Subject	Temozolomide	Small molecule	1000 mg/m2	—

Study of Temzolomide and Gleevec in Advanced Melanoma

Summary

Timeline

Publications

Drugs

Indications